OTCBB ALERTS

[Stockz4O]

GBRC, HYBT, NSHV, ACUR it's "Bulls In The Stable"!
6/20/2007

Jun 20, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Rochester NY: www.otc-advisors.com names (Pink Sheets:GBRC) Global Resource Corp., (OTCBB:HYBT) Hybrid Technologies, Inc. (Pink Sheets:NSHV) Nashville Records and (OTCBB:ACUR) Acura Pharmaceuticals Inc.. it's "Bulls on Parade"!

To feature your publicly traded company in our alerts, email us at [e-mail].

To sign up for our free newsletter, visit http://www.otc-advisors.com.

About Global Resource Corp.

Global Resource Corporation, a development stage company, holds rights to a technology that has various applications to recover energy, such as oil and gas from waste materials. It has an exclusive license with Mobilestream Oil, Inc. for a family of technologies, which allow for the recycling of an automobile tire, as well as permit the economic recovery of oil from sources, such as shale, tar sands, oil resid, and existing oil wells. The company is based in West Berlin, New Jersey.

Recent News(6/20/07):

Global Resource Corporation (OTC: GBRC.PK - News) announced today that they were recognized by the United States Department of Energy as a company that may one day unlock billions of barrels of energy from domestic United States deposits. Patent pending gasification technology, developed by engineers at Global Resource, is applied to various materials to unlock energy in the form of oil and gas, and this technology, when commercialized, may succeed in satisfying domestic energy consumption. The Department of Energy issued a report on Wednesday, June 20, 2007, identifying 25 companies that possess unconventional fuel production technologies. The report includes a profile on Global Resource and its energy production technologies, which can potentially unlock billions of barrels of oil from various oil shale, tar sands, coal and capped oil wells located in the USA.

It is anticipated that the report will be found on the DOE's website later today.

"Our technology may one day allow the United States to rely on its own resources for the country's energy needs, and this report is a testament to the potential our process holds," says Frank Pringle, CEO of Global Resource Corporation. "The experts at the DOE see value in our system, and we are honored to be counted among the giants of the petro-chemical industry as a company that may one day help solve the global energy crisis." The technology gasifies hydrocarbons, the chemical building blocks of oil and gas products, which are found in oil shale, tar sands, coal, capped oil wells and other natural resources. However, unlike other petroleum production processes, Global Resource has discovered a way to cut carbon monoxide and carbon dioxide emissions. Since no oxygen is introduced into the process, and the process is performed in a closed-loop vacuum, harmful pollutants are eliminated.

Representatives from the DOE have reviewed Global Resource's technology and process in-person at the Company's test facility in southern New Jersey. DOE experts witnessed tests performed in Global Resource's emissions-free laboratory unit and analyzed tests preformed on various petro-chemical byproducts. High frequency microwaves are applied to shale, tar sands, resid oil, coal and resources, to heat and gasify hydrocarbons. Those gases condense when they travel through a closed-loop system, creating fuel grade gases and oil, and are collected for storage and transportation. A cutting edge gas chromatograph analyzes the oil and gases to evaluate what fuels have been derived in the process at Global's site.

Global Resource's patent pending technology has been proven in laboratory conditions, and the process is designed to be a cost and energy efficient system. Representatives from major energy companies and emerging energy sectors have visited Global Resource on multiple occasions and have demonstrated faith in the viability of the technology. The process breaks down existing domestic energy sources and produces methane, diesel fuel and heating oil in vast quantities. When commercialized and built on a larger scale, Global Resource's technology will potentially produce oil and multiple gases with minimal refining, energy input, and cost and most importantly without harmful green house gases.

About Hybrid Technologies, Inc.

Hybrid Technologies, Inc., (NASD OTCBB: HYBT) was incorporated in Nevada in 2000 and is a development stage technology company that is focusing its resources and efforts on the development and marketing of lithium powered vehicles, products, commercial and residential properties. Everything from scooters, bicycles, mopeds, motorcycles, cars and homes are successfully being converted to zero emission, lithium powered vehicles and facilities.

Recent News(6/20/07):

Hybrid Technologies, Inc. (OTC BB:HYBT.OB - News) (www.hybridtechnologies.com), emerging leaders in the development and marketing of lithium-powered products worldwide, is pleased to announce that Hybrid's project manager and project engineers have entered the second stage of a Military project based on a Lithium Electric Drive System (L-E.D.S). Hybrid initiated the development of several Military based platforms using a high performance lithium system. Following a funding proposal directed by the board, Hybrid has successfully developed models which meet military market specifications. This development of Lithium Mil Spec vehicles is following studies of current military operational vehicles with alternate fuel source systems.

Hybrid Technologies is currently not disclosing further details on any military projects and will work through The Department of Defense Communications Released Items to provide further public information.

Hybrid Technologies is currently producing several models of vehicles for commercial and government fleet applications most recently to the Canadian Federal Government. Other Hybrid models such as the L-Smart (Daimler) is in use by the United States Federal Government.

All research and developments, as well as advanced engineering projects, take place at Hybrid's plant in Mooresville, North Carolina.

About Nashville Records

Nashville Records was an old record label back in the 1930's. In 2002 the opportunity to secure the label developed. The Sibbett brothers decided to secure the label and keep its corporate status active but had little intent of working it until Gene's youngest son graduated from high school in 2008. But by late summer 2006 some incredible opportunities presented themselves so the Company decided to make a bold push for an expert management team and co-partners but kept it very confidential, as they did not want anybody in Nashville to know what they were up to and what those opportunities were. Then the management made a bold push to elevate the Company to a public market through a reverse merger.

Recent News(6/19/07):

Nashville Records, Inc. (PINK SHEETS: NSHV - News) investor relations has recently received calls from investors regarding decline in share price and apparent shares sold onto the market. In response, the company has examined all possible selling sources and has identified a breach of contract regarding a previously arranged 504-D issuance of shares. All shares issued from this transaction have been recalled and "Stop Transfer" orders have been issued to the Company's transfer agent. While the shares were legitimately owned by the 504-D purchaser, they were never intended to become free trading and Nashville Records(TM) engaged attorneys to deem the entire contract null and void, and force the return of all shares back to the company. 504-D shares not yet sold into the market are to be returned immediately to the company treasury - all sold shares will have to be re-purchased on the open market and returned to the company treasury.

Between April 12, 2007 and May 1, 2007 the company entered the 504-D offering encompassing two issuances of shares and one transaction that had not resulted in funds being received by the Company.

Upon further review by the Company's securities attorney, an opinion letter was issued and sent to the various parties involved, their legal counsels, and the brokers or market makers who seemed to be trading in the shares.

The offering itself, which was conducted as an exempt intra-state offering in the state of Minnesota, was credible and legally sufficient and was handled by specialized securities attorneys, but it was the opinion of Nashville Records and its securities counsel that the follow-up redistribution of the shares to holders in another State was an unregistered underwriting that not only violated the spirit of the exemption, but State and Federal Securities laws as well.

While the opinion of counsel letter is far too voluminous to publish via a press release, it can be viewed as text on the Company's website, http://www.nashvillerecords.com.

A Minnesota securities attorney will be retained to seek a permanent injunction to halt trading of the tainted shares, possibly with the aid of the Minnesota Securities Department.

Although the company regrets this issuance, it is acting aggressively to find a swift resolution. It is important to company management that transparency with shareholders is maintained regarding evolutionary steps in our development. While the company was founded on expert talent from the music industry, the unique risks associated with being traded on the public market will be minimized in the future by engagement of legal and investment banking advise before actions of this nature are undertaken.

The company's reaction to the contractual breach will eventually result in the forced buyback and return of 25,226,189 shares to the Company treasury. One purchaser in the 504-D offering has voluntarily returned 2,083,333 shares that have been cancelled. The Company assumes that a large portion of the remaining shares may have been sold into market.

About Acura Pharmaceuticals Inc.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of abuse deterrent, abuse resistant, and tamper resistant formulations intended for use in orally administered pharmaceutical products. It develops products based on its Aversion Technology, which is applicable to immediate release and extended release, orally administered tablets and capsules, and can be formulated into orally administered tablets or capsules containing commonly utilized opioid active pharmaceutical ingredients or other potentially abuseable drugs. The company's lead product candidate includes OxyADF tablets, which are in various stages of clinical trials, incorporates the Aversion Technology with oxycodone HCl as the active analgesic ingredient in an immediate release tablet intended for oral administration. In addition, it engages in the formulation development of additional immediate release product candidates intended for oral administration incorporating Aversion Technology, including hydrocodone bitartrate with acetaminophen tablets, hydromorphone HCl tablets, and Oxycodone HCl with acetaminophen. The company was founded in 1935 and is is based in Palatine, Illinois.

Recent News(6/19/07):

Acura Pharmaceuticals, Inc. (OTC Bulletin Board: ACUR - News; the Company) today announced it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a pivotal Phase 3 trial of OxyADF Tablets. A SPA is a process in which the FDA provides evaluation and guidance on protocols for Phase 3 clinical trials. The FDA's agreement to the SPA confirms that the design, primary endpoint, and planned statistical analyses of the study adequately addresses the requirements supporting a New Drug Application (NDA) submission for OxyADF Tablets. The FDA previously communicated to the Company that only one successful Phase 3 pivotal study will be required prior to NDA submission. While there can be no assurance as to the safety or efficacy results of the Phase 3 trial for OxyADF Tablets, if the Company follows the agreed-upon protocol, then much of the uncertainty associated with the design of this study should be removed. A SPA is binding upon the FDA unless the trial protocol is changed by the Company or a substantial scientific issue essential to determining safety or efficacy is identified after the testing begins. OxyADF Tablet Pivotal Phase 3 Study Design The OxyADF Tablet pivotal trial, AP-ADF-105 (Study 105), is titled "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Repeat- dose Study of the Safety and Efficacy of OxyADF (oxycodone HCl and niacin) Tablets for the Treatment of Acute, Moderate to Severe Postoperative Pain Following Bunionectomy Surgery in Adult Patients." Study 105 is a 3-arm study comparing two dose levels of OxyADF Tablets to placebo. Study medication in all three study arms will be administered every six hours for 48 hours following the onset of moderate to severe pain following surgery. Study 105 is anticipated to enroll 135 patients per arm (approximately 405 patients in total). In May 2007, in anticipation of receiving FDA agreement to the SPA, the Company executed a Clinical Trial Development Agreement with a leading Contract Research Organization and commenced preliminary start-up activities required prior to beginning patient enrollment. However, enrollment of patients in Study 105 remains dependent upon the Company's ability to secure adequate near-term funding for the study and related operating expenses, of which no assurance can be given. In addition, the completion of Study 105 will be dependent upon the Company's ability to secure adequate longer-term funding or a collaboration agreement with a strategic partner, of which no assurance can be given.

About OxyADF Tablets

OxyADF (oxycodone HCl/niacin) Tablets, the Company's lead product candidate with Aversion (abuse deterrent) Technology, are orally administered immediate release tablets containing oxycodone HCl as an active analgesic ingredient, a sub therapeutic amount of niacin and several functional inactive ingredients. The Company intends to file a 505(b)(2) NDA for OxyADF Tablets with an anticipated indication for treating moderate to moderately severe pain. OxyADF Tablets are intended to effectively treat moderate to moderately severe pain while also discouraging the three most common methods of misuse and abuse including (i) intravenous injection of dissolved tablets, (ii) nasal snorting of crushed tablets and (iii) intentional swallowing of excessive numbers of tablets. The Company anticipates that OxyADF Tablets will be scheduled as a C-II product by the U.S. Drug Enforcement Administration (DEA).

OxyADF Tablet Commercial Manufacturing Site Qualification Plan

In addition to agreement for the SPA, the Company has also received written FDA guidance confirming agreement in all material respects with the Company's proposed commercial manufacturing site qualification plan. The Company is currently in discussions with prospective commercial product suppliers and intends to include relevant data from the selected supplier's commercial manufacturing site in the NDA submission for OxyADF Tablets. OxyADF Tablets utilize a dry blend, direct compression manufacturing process. This process requires commonly utilized blending and tablet compression equipment and, compared to other tablet product formulations, is simple and economical.

About the OxyADF Tablet Market Opportunity

Based on market research data purchased by the Company from IMS Health, for the 12 months ended September 30, 2006, approximately 227 million total prescriptions (brands and generics combined) were dispensed in the U.S. for immediate release and extended release tablet and capsule forms of opioid analgesics. Of these dispensed prescriptions, approximately 13 million were for extended release products (usually administered every 8 to 24 hours) and 214 million were for immediate release products (usually administered every 4 to 6 hours). Extended release products are more commonly prescribed for relief of pain for durations ranging from a few weeks to several months or longer. Immediate release products are more commonly prescribed for relief of pain for durations of generally less than 30 days. According to data published in The National Survey on Drug Use and Health Report, Issue 22, 2006, immediate release opioid containing pain relievers are used non-medically (including through misuse and abuse) approximately ten-fold more often than extended release products. The Company's primary market research (the Company Market Research) involving more than 1,000 physicians routinely prescribing opioids, suggests that OxyADF Tablets will be considered by these physicians for use in both the immediate release and extended release market segments. In addition, the Company Market Research indicates that physicians will switch a certain percentage of their prescriptions to OxyADF Tablets from other C-II oxycodone HCl containing products and also from C-III products like hydrocodone with acetaminophen, although there can be no assurance that this will be the case.

Cash Reserves

The Company estimates that its current cash reserves will fund operations, excluding any outlays for Study 105, through mid July 2007. To continue operating thereafter and to initiate patient enrollment in Study 105, the Company must raise additional financing or enter into appropriate collaboration agreements with third parties providing for cash payments to the Company. No assurance can be given that the Company will be successful in obtaining any such financing or in securing collaborative agreements with third parties on acceptable terms, if at all, or if secured, that such financing or collaborative agreements will provide for payments to the Company sufficient to continue funding operations. In the absence of such financing or third-party collaborative agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws.